Agilent Technologiesvs.Revvity
A vs RVTY · both in Life science tools, part of the Medicine, pharma & life science value chain: Instruments, reagents and equipment for research, development and production.
Agilent Technologies is about 3.2× larger than Revvity by market cap; Agilent Technologies trades at the lower P/E (29.4 vs 55.1); year to date, Revvity leads (+27.1% vs +12.8%).
Side by side
| A | RVTY | |
|---|---|---|
| Market cap | $41.5B | $13.1B |
| Price | $154.77 | $124.84 |
| Today | +0.9% | +1.5% |
| Return YTD | +12.8% | +27.1% |
| Return 1Y | +26.1% | +30.6% |
| P/E | 29.4 | 55.1 |
| P/S | 5.7 | 4.5 |
| P/B | 5.8 | 1.8 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Agilent TechnologiesA
Laboratory analysis is the business: LC/MS and other analytical instruments, sold with the consumables and diagnostic reagents that keep them running.
Full A profile →RevvityRVTY
Newborn and genetic screening is the clinical end of the business; the rest supplies reagents and software to research laboratories.
Full RVTY profile →More A & RVTY comparisons
Other head-to-heads in the Life science tools segment.
See where A and RVTY sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →